XERS - Earnings call transcript Q1 2024 | Xeris Biopharma Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, everyone, and welcome to the Xeris Biopharma First Quarter 2024 Financial Results Conference Call and Webcast. My name is Sep, and I'll be the operator for your call today. [Operator Instructions] I will now hand the floor over to Alison Way to begin the call. Please go ahead when you're ready.

Allison Wey

Thank you, John. to XXXX welcome Call Results and Webcast. and morning, First Financial Quarter Conference Good issued release, our found we morning, This press website. on which our be can We're and Edick, our by joined Steven CFO. and Pieper, Chairman this morning CEO; Paul those could Instructions] differ are remind that statements. to and subject forward-looking statements the to this would prospects materially plans, that forward-looking you company's contain risks Before expectations, we cause will and [Operator to I concerning like from actual begin, results call financial uncertainties performance

For risk our refer report release and more will risks, our to please annual call. that information on factors, such be earnings press this filed on our SEC and Form XX-K in following including filings

this in forward-looking applicable this any to We over to call obligations statements disclaim date law. Paul. as call such turn Any the of now and statements. call to I'll update views subject our only represent of the

Paul Edick

day. Allison. Thanks, Good

thanking growth momentum XXXX. way headline tighten second $XXX to company, an contributed we making Let is who in at dedicated revenue call again start enable the from and million patients meaningful every including quarter XX% year, bottom revenue by start outstanding $XXX guidance, with health total we level for that The serve, great day. total the to some our million, for giving last care us already me today's versus the a in executes to a building team the delivering providers in quarter, everyone confidence raising the for us Xeris to high the

together subcutaneous exclusive last Monday, first products. XX% across performance our Recorlev, have TEPEZZA quarter by with a develop, in a agreement XeriJect license and the entering manufacture [ our combined thyroid and had formulation high we the technology of commercialize executed level, compared disease. grew of we in all using announced recall sales commercial a strong At partnership collaboration that And another BetaBionics. license On new a agreement to net our Gvoke eye announced year. and ] Keveyis in X worldwide January, we you'll Amgen into to technology continued

the on the continued I deliver in already by momentum XXXX. all to believe excited into and fronts well we're momentum positioned I'm April, generated we've

patient performance the commercial net products in increase with a compared to quarter, We're last Let's excited Recorlev XXX% into the -- patient a with year. and those new referrals going quarter. We to Recorlev record progress, of pace. start quarterly to at Recorlev's of a We're drug on with very $XX.X driving referrals first our converting today. record in million the grew sales for start patients

to unique the significant in treating patient quarter new number increase quarter the previous the As not with average XXXX. demand number and of underlying first in has patient and growing with a the patients referrals by growth increase drug recognize also fueled patient our in with prescribers continues patients to referral but was importantly, only unique starts, of shown referrals first XX% continue prescribers of grow. significant Recorlev. Growth on The value XXX% increasing by patient versus versus who grow, pipeline the quarter the

this levels relying the is treats Cushing's. in patients prescribers body. Recorlev bears in actually Recorlev treatment Cushing's of Recorlev is advantage category It other Recorlev an ideal dynamic Cushing's market. we the for versus see in The recognize increasingly cortisol conditions potential that used in that an with prescribers repeating key products therapy recognize that Increasingly, with by tremendous for the most normalizing

continued Recorlev growth. we assistance Capitalizing to support on this team momentum, add to resources in our patient continue commercial and of

by quarter quarter growing face remains the sales and than stronger Unpredictably, the Keveyis driven decline in we for by We're existing new competition Keveyis I see payer stronger first patient the to X% for XXXX much we than as happen stated Keveyis as anticipated, the resilient as Keveyis underlying quarter rapidly in to our in year, ability start as we quarter brand expected and Moving demand anticipated, a first of first in was to find we didn't competition. that the Keveyis. with and generic remains resets. which continued patients believe last year. a we generic off in last patients. driven compared expected. retain This start incredibly well Keveyis to The to

into sales exceeded This our importantly, expectations in we're second carry the that also And the significantly quarter. momentum for well resulted quarter. this seeing

new primary the and to maintaining to our finding to contribution to paralysis be community committed continues commercial are We patients periodic Keveyis' the key portfolio.

the Gvoke's Moving continued growth grew of quarter in Gvoke Gvoke's market sales to February. increased compared increase prescriptions in largely sales driven the Gvoke. while share year, net glucagon This by XX% and XX%. was approximately in and gain January net market prior to the

figures April, The of share total off XX%. with in prescriptions glucagon started weekly over was As growth market year the with trends total of published well. as Gvoke the consistent last historical

grew the a prior compared year. in to healthy glucagon market XX% reference, For February,

and breach However, utilization March their glucagon claims all Change their announced February assistance importantly, shut were late the Healthcare systems. impacted negatively market, our and when co-pay program and processing cybersecurity our the of in script growth, down

and chains through early inventory did it the wholesalers. by February also of the impact assistance only situation, for in by resulted that tightening For many cybersecurity between unable starting were card first calculate many means our Not co-pay and our prescription struggled several that Gvoke much prescription of sales breach Change largest April. to utilization clearing through net U.S. Gvoke the retail Healthcare pharmacy a based to had certain Healthcare are impact normal shutdown of This quarter. dispense adjudicates familiar the Gvoke adjudication prescriptions in temporary in million in house the our especially pharmacies, less meant as of as patients This prescriptions is Change this co-pay essentially many $X that processing, on weeks. on those who payers. pharmacies claims We program with the but prevented utilize change the

they impact Recorlev able single means or alternate to not quickly on Keveyis To prescription that be through to switch was a pharmacy unprecedented have adjudication. clear, as are specialty of this situation dispensed similar a did

Importantly, in wholesaler the recent seen Gvoke will quarter. of trends we for has prescription prescription fulfillment glucagon in April historical second script have return May, week most of end increased believe by total late the commensurate to prescription recovery new Based data, and Gvoke and the the market to and growth with we purchases market share early demand. on XX%, new

would Gvoke in total we expectations for revenue for were To have exceeded be in not Healthcare it very we clear, situation, quarter. product the the Change believe

Moving to platforms. technology our

is is our growing XeriSol and enabled part Our science and partnerships overall Not of enabling of considerable of important it's into XeriJect that growing the development platform also revenue the Gvoke, development. has but our a what could well enterprise formulation increasingly deliver levothyroxine number and product, science our pipeline only future.

worldwide and in pump we a entered of for of with development our an announced license partnership, unique exclusive for bihormonal we liquid that and collaboration latest BetaBionics agreement XeriSol-based a systems. use pumps On Monday, glucagon commercialization or into new formulation stable on the and

be not to gevo. Just this is clear,

for specifically gun book use in new a formulating are a pump. We

pumps through development glucagon to receive have and low systems. potential on payments sales of royalties double-digit this and pump future Through partnership, clinical for the we Xeris

molecules. the announced develop, initial license the completed Some in January, will other of in in development quarter, to for formulation Regeneron's agreement the thyroid and nonclinical and subcutaneous our commercialize next formulation we Amgen as notable over both tepratukomab Regeneron, executed XeriJect exclusive eye have place months. disease. manufacture using evaluations With technology developments a we X take stability

continued platform, additional clinical that milestone. commercialization which potentially would molecules trigger executing Assuming onetime to for of option the could development, of license any success, in the their lead a further

our will on program, subcutaneous Now of potential injection. the the study We available second be end and the of a II XeriSol completed to by once-weekly update quarter. data an Phase clinical successfully levothyroxine

a as As requesting alignment dose this the program. meeting anticipate for can with pivotal this design, Phase help year. study our of study early conversion as start FDA Phase reminder, If III to Phase We end later that a a an gain mid-XXXX. data we FDA proposal we on inform will oral III II

overriding message is today. Here my

product technology partnerships. and portfolio growth, generating Our significant new commercial meaningful adding we are is

meet across uncontrollable as We our XXXX. temporary tightening future is outlook despite gives impact such of in Healthcare. for our board exceed to events external the the what performance confidence and continue us or continued expectations Change guidance revenue That

are raising low $XXX We the range our million revenue $XXX total from to end million. of

$XXX to million total million. revenue $XXX is revised now guidance Our

our at commercial business performance is business in investments while us overall and XXXX. pipeline, internal $XX our million business, cash our strong to also incremental guidance of year-end to million make our Our technology maintaining $XX enabling

build to enterprise. healthy self-sustaining a continue We

for additional Steve the I'll financial over on now to performance. turn call details our

Steven Pieper

everyone. Paul, Thanks, morning, and good

All compared to products We XX% to revenue million, X total of a $XX.X As revenue our last last of XX% compared with are roughly increase we quarter Paul start. quarter to of a year, mentioned, the $XX.X ended to off commercial compared revenue net the and product grew last million, first great year. in year. a increase

to last XX% compared Recorlev Recorlev year, average X% net for XXX% was increasing of driven This the XXXX. with to the Starting number the increase quarter. year the was fourth an on revenue, and prior patients growth from from revenue quarter $XX.X fourth primarily Recorlev quarter, a XXX% first and compared increase by million

patient the growth for and a by quarter. which to of We XX% consistently year the to last continue be Recorlev, compared fourth been by demand pipeline fueled compared growing to referrals, encouraged has increasing XX%

Recorlev Based to fourth to the off patient XXXX quarter, revenue we year start resources beyond. the our quarter add of to expansion, a early support success growth in and and and field field this will second drive strong continue

was net the $XX.X be same to continues quarter. the representing revenue Moving in Keveyis estimate our period X% for Keveyis, internal compared resilient last to the year. and increase actually quarter beat to a Keveyis first million,

be Our defend and brand strategy Keveyis in to continues to successful. invest

saw fourth the slight due a into continuing to we in quarter, quarter, the pressure. demand decrease patient in and generic Starting first

anticipated was increase pricing. decrease However, in this we offset and by was an than lower

quarter. of to continues compared Care performance primary paralysis Keveyis the referrals which increased the brand, Connections, the patient patients. XX% the year and including offers support This periodic reinforce Our to strength therapy XX% for to Xeris and prior compared best-in-class fourth

$XX.X last Gvoke was first revenue for compared Gvoke, same XX% the increase to period year. representing million to the a net Moving quarter,

grew share period quarter quarter, period same the same to increase share Gvoke of year, first XX%, the a prescriptions from the with in last ended market XX% last and year. Importantly, Gvoke the compared X%

we sales Gvoke we in was had by breach, the mentioned, cybersecurity a million revenue estimate believe Gvoke's which net Healthcare temporary Paul impact on growth as the As net quarter. $X Change and that negatively as first much impacted

as data are the from well as second for prescriptions, X,XXX end and strong be largely we the seeing Healthcare the impacts effects that the Looking recent the quarter, second exceeded demand cybersecurity patient believe breach Gvoke which We by ahead temporary of weekly resolved orders quarter. in wholesalers. increased of Change to our will most underlying the

Looking we the total million $XXX ahead to the original full guidance to revised of are raising million the revenue guidance million the to our by to range, $XXX low million. $XXX from with end guidance going of year, $XXX tightening

of reflect from strong our are We guidance performance contributions our the expected and Keveyis partnerships. Recorlev, tightening of resilience to technology the the continued

Moving sold P&L. by last fourth to a product was quarter of increase Cost was down million, the $X compared quarter driven the year. the XX% This sales. in higher same increase goods

last R&D remarks in $X expenses an strategic year. pipeline, technology notably and in my year. period costs result increase and March, quarter, our has the of partnership the $X.X development and to were million same with Consistent million business, we increase for levothyroxine an which continue this our will emerging our make investments in in compared to Research

expense administrative to increase $XX.X general increase by Selling, million by quarter, headquarter in and driven the expenses personnel related quarter. XXXX, a April same our last the the primarily and which $X.X was year. commenced fourth lease, expansion a higher in rent for to compared cost, field an period driven million were of This modest

making incremental drive the XXXX are we to increase this growth modest for to we ahead year, are the projecting includes in SG&A beyond. Recorlev business in which the impact the year, investment full and of Looking a

the Moving loan previous maintain to a $XX million of $XX.X we revised We are guidance cash. as which the we million. of our as included to in From million, term continue cash, approximately guidance our net ended $XX perspective, proceeds revenue investments Recorlev the the cash in Hayfin $XX guidance considers with refinancing to making million which quarter business. well from additional

enterprise. We expense able a these are as our revenue make with strong result to growth, investments of of continued management combined disciplined

to forward to and we in off great is a XXXX, to build momentum. look continuing this Xeris start on

lines With the that, operator, open please questions. for

Operator

first Livnat [Operator Oren Wainwright. from from Instructions] H.C. The question comes

Oren Livnat

couple. a got I

essentially the essentially end. from it tightening Can have guidance. going QX, follow-ups. Is conservative outperform to clarify, the First, generic assume impact? maintaining continuing up just on decline in significant the a bottom assumptions I as that Keveyis, your tightening on you bottom up but forward And

Paul Edick

it's conservative less what quarter Actually, what have excited the previously, raising Paul. on Oren, to we we The bottom Keveyis. guided It hit about what decline in exceeded And contrary thereafter. we pretty quarter. in anticipated. first being We're thought the we'd get the is said that happened some first and we

little is. surprised The Keveyis bit softening to a less thought. is bit but what therefore, very than the close how a what decline some there, even first be with, little hit quarter resilient there thought, by wasn't we're we and we pleased Still, will

Steven Pieper

just we're raise across bottom our end. as gives us really of brands, that that to I and Oren, that seeing into continue to confidence Yes, all QX momentum add would that, well the

Oren Livnat

you to levo, of And II, you remind data What you point? I -- see data. completed any anything us months Great. and crunch? is to And matter on more I in is see? delay that work just said successfully guess think success seeing data, it what you a for is guess, this just does couple still a Phase of waiting to at Can this need you're Or through entail? still there there I

Paul Edick

We've is. gotten visit, matter study. number the We data last the patient It's needed. got patients We've We've successful of all through just we of patient, a everybody records. the hit crunch. completion last

just crunching Now all it's of through data. matter a the

multiple Phase study, designed whether do study the still that healthy we multiple is from If patients. conversion. is of the purpose confirm a levels our it you I different This conversion oral to recall, was the confirm or the when was in doses hypothyroid to study at liquid. case volunteer Xx ratio dosage to that actual In

Oren Livnat

difference between thyroid if patients this say at you any point? there Can was healthy and

Paul Edick

We line gotten top have the yet. not data

Oren Livnat

have all impact. additional All Gvoke, impact of in had of it that been that I little inclusive seasonal of sort know lastly, you on sounds cyberattack everything $X was of million like underlying say would $X right. And Great. this headwinds. just quantifying just this what that the sales that versus million? net normal for Can sort destocking? quarter, you Is the impact expected demand a and thanks destocking already caused

Steven Pieper

It's yes. all in,

we've it you would see So scripts timing wholesaler in seen. it's was which pretty And with well significantly the of timing as the underlying attack. which as demand, directly destocking, historically more cyber was the correlated pronounced the than of

Oren Livnat

forward, top unit mean, I expect look some is hangover stock in, we net that, going -- right economics different from there or doing On perspective otherwise any normally great. than obviously, in should or lost maybe the that ship? XQ? should do in to and we you you general? be of So to might do you scripts would And Like have in to additional salvage patients patient XQ have assistance rebound

Paul Edick

of period another increased a to them, be even was We to patient, believe for extra. the see. -- that already going they're co-pay We of we'll and believe written get anything of if to a the not we have there a stacking whether up if The up there may -- see back we're what's X, pick been going a do barometer is may prescriptions X but But have rebound. abandonment. card they pretty of bit don't it We starting good written. or with a we'll some probably get on don't don't we pharmacies, Yes. little that prescription get those patients,

patients. those get still we'll So

Steven Pieper

would say, inventory around I in I anticipate your any what wholesaler inventory to build say. levels, to would question running Oren, our total, is not I lower first Whether wholesalers are And up or We seen. what don't levels. be that, inventory would it at remains say low they Yes. historically going

but remains but if be seen. there, So upside, no potential that downside for anything, to really

Operator

from Leerink Ruiz next comes question from Our Partners. Clarissa

Roanna Clarissa Ruiz

BetaBionics. wanted So about ask collaboration to I the with

And So do this think opportunity line time big possible could what be? to that pump? is you the glucagon how of commercialization approximate market

Paul Edick

algorithm pump, it have that and and detects X market a little at the that little a your they've with I your insulin the glucose developing more we've that would and of done obviously, think you What the Beta bit the for the been provide on detects as with have perfected process can of is in an bi-hormonal a for day. question Well, insulin a each give bit They component. [indiscernible] of is Beta Bionics hormone end decades. of being the they pump Bionics, necessary.

deal facilitate the Our will second hormone.

glucagon have II, of Phase be lot put point, be in can of with facilitate clinical the patients. on years of with glucagon hormones could pump we development, that liquid-stable further it hopefully, next included. the the So closed-loop both few have At system well pump pump approval, the hormones. that glycemic in a some part very to X Anybody III a want is an with a important to could today, who's control Phase for

So an partnership it important our the mean for it's because new of glucagon for us, formulation sales different could significant future. in of

Roanna Clarissa Ruiz

seems the of quarter, that year? And going to the growth Got rest Could on it. weekly recent for great some the about patient into expect helps. you be you anything what you talk quarter? trends That in if saw really traction. showing And and referrals second in you're question second Recorlev. seeing the

Paul Edick

Yes.

We April right here great. and -- So Gvoke matter, the did, outstanding. imagine. what not both Recorlev I hawk, but more that sitting here been all even for a April for We're Keveyis April in preview has are looking can referrals today, track weekly in as if to and me. don't growth encouraging. going And been But data of front you the like have has it you

Operator

Our from next from David question Piper comes Sandler. Amsellem

Unknown Analyst

This on is Skyler for David.

more on thought shows naive experience and overall, understood? patient you how seeing on the of about the prevalence can light much in study treatment catalyst Recorlev, the the you're patient versus you're just might what about higher data Cushing's addressable from than First, the previously And population just thinking talk footprint of trajectory? be

Paul Edick

we is this been question. the the been than -- has patient category historically without viewed much addressable Great larger believe population way than Yes. questions. that it's

who that this your tremendous going So getting patients we And people. bit first been these expect. have of products. in of a other question, churn are To have a would lot as the category as you on a we're They There's see opportunity. quite ill on. part

We are Korlym, simply patients normalizes product from getting quite our a symptomatically. few We because don't just cortisol. treat

we believe, gives getting an that, we're in board. patients essence, us the advantage. across from But So

And who've use interestingly, Recorlev tried it physicians line. to are first starting

getting patients, of drug-naive So of be category lifespan already rare the early kind to kind product we're first-line a in this patients. this in getting in which of disease is

I And that. by degree. encouraged think very referral driving that's what's pipeline we're to So large a the

David Amsellem

about rescue the opportunity some do helpful. tailwind then the there? are growth penetration be to is And underlying X think category, How increase you of overall That just of more. the And what overall would Great. you glucagon the market? thinking the

Paul Edick

rescue in your part question. glucagon, didn't I The hear of the first category

David Amsellem

penetration you overall just will Yes, market? and opportunity think of there that what increase

Paul Edick

at some XX%. of was growth the to if I Yes. look it total growth. rate get to double-digit growing on, Pre-pandemic, XX%, we back seen what's expect it time. mean fully you But we've in market over fluctuation the going

the increasing growth So growth prescriptions rate which the potential there's driving our that What's important is regardless or the share there. dramatically. momentum of of growth, good of overall is market, of the new we're of more majority even

the X% If it, few X% it's months. you grown or look at in last

our share So increases, as is market growth increasing. the

future rescue XX who So for million well people And there have all and Gvoke. out really actually bodes are million a device one. there X need the only that for

opportunity. there's tremendous So

Operator

next comes Knickerbocker Chase Our question from from Craig-Hallum.

Unknown Analyst

you generic? for year? Conor This start to Can the seeing on this update the we an to Keveyis give payers treatment Are continues seems Chase. like switching is It going in hold us from any to force on there.

Paul Edick

with as payers I -- we're patient take payers rapidly some we've happening the to patient forcing seeing It's had are anticipated. forcing be seeing as just We as switch. insurance would no had opportunity we payer loss, figured have opportunity that we saying but conversion are the quarter, We first thought. resets mean aggressive We're not in as would the not pretty about aggressively not loss.

reasonably of to don't generic The actually services go And we're a coming that that their who mentor they're a have is provide. forced are they're to support high there's patients they're help with brand used big anymore percentage other sort part they thing on a They seeing don't is of a that back. lot of the a reentry that don't the are surrounded life to. the support into patient that when generics get

is and better part -- So little them getting of yes, XXXX to been a than we're performing had we've seeing, pretty not a happen. that And we've a good our going surprised, overall we're the losing some, lot And way. what quite but a but is we're knowing guidance, resilience Keveyis been in of few we back. in a conservative that was really

Unknown Analyst

maybe you required partnership for into And then to need What what can the year-end? else Bionics do you ready? get on is Beta Great. dive

Paul Edick

Our is pretty role simple.

we that It's be will the a be than that. of We'll are new is Gvoke. already pump. components in glucagon, all pump-specific formulate -- a of which of will will what glucagon compatible very to formulate version different starting the with We

Bionics. -- expect can whatever move We to That's will Beta And a this of to system on then XXX% all own have to their Bionics for Beta confirm to and testing And II make the program Bionics then year. III Phase get them. we we Beta assuming dual-hormone done program, a will Phase some that give success. do into then

and and are programs with those drug a because helping company. and them things will drug more than a studies they're that like We company they through consulting support advice device

terms trial. that a components in provide and support drug we'll the of advice So of

we support into that, and beyond We on double-digit get III. to will well we'll manufacture supply a continue Phase them a supply, both commercialization. for we low But and markup get royalty, and Phase II

Operator

Rohan Matha from comes from question Oppenheimer. next Our

Unknown Analyst

is Leland Gereshell. on Rohan This for

you are developing possible respect or about with When a couple me. collaboration? in house viewing from Just in forward the subcu some levo opportunity, performance drug engaging you paths the think how maybe to either

Paul Edick

We're both. open to

We we cash financial the and grow that have in-house, it our future, develop as resources to have start the the capabilities believe more to balance sheet. and assets deliver in to the especially we commercial

We can oral perfect to doesn't prices, it. the than be ready the of option, people than done, could develop variable regardless ourselves. prices, not would organization overall population, the even a tract, are a have of today's for a good We dramatically this blood can't the time who the but segment those about By we that's people think gastrointestinal the segment our levels, it XX% which, bigger would who who whom not more it's of tolerate see getting capable it be That segment. $X will a future absorption, at billion in a for drug patients launching commercially. get partner obviate commercialization, potential to make of for it we be

a So we would if think be opportunity. And it's it bigger. for even to purposes making the partner, huge it of we choose

Unknown Analyst

with should the on see year And front? and partnership, expect Regeneron to business development updates else the it. maybe any respect to this anything Got we

Paul Edick

they're to people We're it's We're the -- us more more companies us on we're having talking the expect It while development from months, front. as our always I Beta already their the that. a this year I X in deal doing -- business of active end announcements any stability approach Bionics business. over technologies they're work. done. that to always about the and comments with next took think more get and I my Regeneron, don't do we said

Operator

follow-up is Livnat question next Wainwright. at H.C. a Oren Our from

Oren Livnat

mostly bit long-term sales. new But titration the Are expand obviously I'm ongoing mentioned investments to part the are now on behind this patients and product? of in those deepen potential our to the those what I hub want for can and services? Or time incremental bit more year presence? patients outperformed follow-up access on you're making on actually over that's I patients, And Recorlev. think dose regarding longer-term an you broaden a just that. curious the on up also, and market the you field putting a It important seeing you're expectations or field of trends you of reps

Paul Edick

basis. -- Oren, or patient dose seeing up there. we there's about X on -- The thanks, so an X The let titration. so titration start So in like with me are individual

However, new end dose entry patient is quickly so at patients we're moving patients dose the at many of fast at the starting adding starting adding point per that at dose. quickly so low the not so the we're that the average because

Over more time, see based revenue start up to impact it's larger the [indiscernible]. subset we'll a patients, base of with but on on way the titration, that's

out and force, of don't field we're force. like XX adding range XX, resources, get We add field big. to to, the time, add just to to to is continue reps XX services, -- adding time but the terms In bit because patient continue be the field over to so the little would the support a of up we disrupt the force. to will to We want to XX, we opportunity

Unknown Analyst

[indiscernible].

Paul Edick

believe... John this XX, I I to I'm looking see at if answer. could get Shannon

John Shannon

now. XX

Paul Edick

XX We of as have now.

will another... add We

John Shannon

XX. to XX

Paul Edick

Yes.

Oren Livnat

Over time.

Paul Edick

Yes.

Oren Livnat

Okay.

Paul Edick

next quarters. of the couple Over

Operator

Close next Our Michelle from from company sorry, Close. Kelly next -- comes is question

Unknown Analyst

The national came given. people data have earlier data CDC hospital landing out that from XXX,XXX. this showing year New last the to closer XXX,XXX report diabetes -- the dropped to in the time severe from statistics during [indiscernible] was

for So this. thank so you much

of people but other could a see people like I you you partnerships, XX% corporate would the like maybe have still had talk if numbers the done? in what to hospital. as just the maybe be this X AID It obviously, be to else else partnerships. on gone hospital, This . [indiscernible] about does going terms to up. big can those seem as well. was What of were admitted DKA in wondering probably philanthropic, You've impact should this number

Paul Edick

having ready-to-use impact. we're such I have going an impact. people it's rescue as an with believe do -- do to I HypoPen believe more And devices Gvoke,

at situation. situation. getting mortality look you to they that is now and should focus ER, correct. rescue the trying the a get if to category, you've to admitted insulin we're mandatory. ready-to-use absolutely would really The whenever been important be while are reengage absolutely co-prescribe hospital. still When thing geo getting have be you severe allergy equally that People siponourea, should are this, know. for still This an There the on as HypoPen, going life-threatening a you a got You're health don't a prescription to It and still a a a with or associated they write the rare is care allergy professionals product. right or most for

It in health or they the professional whenever is automatically think number I to motivated one. you've to that prescribe their say, perfectly if really HypoPen for Gvoke been make condition number needs it's of community That's orders to can insulin. the office could standing job sure prescribe me. And managing to Even your to anybody. two, continue decades, be it happen be the care

we So to do. those X things are need the

Unknown Analyst

Yes. we're also. are really know clinicians Thank of who overworked you so much. to the I all all grateful really just

community I questions really the from coming patient and think also be doable. it so that And helpful. forth, also also So would seems

for you impact. very, thank your much all very incredible of So

Paul Edick

it. Appreciate Thank you.

Operator

questions further no call. on have We the

for floor closing So back Edick I to remarks. hand the Paul

Paul Edick

Thank you.

date. -- another As to delivered and proud performance you are quarter of very growth our heard, of growth, we've

be of another enterprise, expect very We in XXXX. which the April, proud in to all can tremendous seen We've the we and we look continue of. year in of momentum acceleration forward growing balance to a

Operator

call. concludes This joining. all the very for you much Thank conference

Xeris Biopharma (XERS) 9 May 242024 Q1 Earnings call transcript